Tandem Diabetes Care, Inc. Stock
Equities
TNDM
US8753722037
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
51.23 USD | -4.12% | -0.97% | +73.19% |
Financials (USD)
Sales 2024 * | 869M | Sales 2025 * | 960M | Capitalization | 3.31B |
---|---|---|---|---|---|
Net income 2024 * | -109M | Net income 2025 * | -72M | EV / Sales 2024 * | 3.64 x |
Net cash position 2024 * | 145M | Net cash position 2025 * | 111M | EV / Sales 2025 * | 3.33 x |
P/E ratio 2024 * |
-31.3
x | P/E ratio 2025 * |
-46.9
x | Employees | 2,400 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.23% |
Latest transcript on Tandem Diabetes Care, Inc.
1 day | -4.12% | ||
1 week | -0.97% | ||
1 month | +39.63% | ||
3 months | +92.38% | ||
6 months | +153.11% | ||
Current year | +73.19% |
Managers | Title | Age | Since |
---|---|---|---|
John Sheridan
CEO | Chief Executive Officer | 68 | 13-02-28 |
Leigh Vosseller
DFI | Director of Finance/CFO | 51 | 13-08-31 |
Shannon Hansen
CMP | Compliance Officer | 58 | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 19-01-02 | |
Director/Board Member | 64 | 13-06-30 | |
John Sheridan
CEO | Chief Executive Officer | 68 | 13-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.45% | 2 M€ | -.--% | ||
0.32% | 430 M€ | -.--% | ||
0.10% | 12 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 51.23 | -4.12% | 1,425,696 |
24-05-30 | 53.43 | +3.25% | 1,520,380 |
24-05-29 | 51.75 | -2.17% | 897,077 |
24-05-28 | 52.9 | +2.26% | 1,125,972 |
24-05-24 | 51.73 | +4.13% | 1,037,730 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+73.19% | 3.31B | |
-7.16% | 178B | |
-4.86% | 67.04B | |
-4.28% | 47.24B | |
+10.32% | 44.62B | |
+8.14% | 42.5B | |
+15.76% | 29.99B | |
+15.53% | 25.22B | |
-5.88% | 24.14B | |
-5.38% | 23.69B |
- Stock Market
- Equities
- TNDM Stock